Testing effectiveness (Phase 2)Study completedNCT00583349What this trial is testingIntravesicular Abraxane for Treatment-Refractory Bladder CancerWho this might be right forBladder Cancer Columbia University 46
Not applicableNot Yet RecruitingNCT07744958What this trial is testingRESTORE-BLADDER (REgistry on STrategies for Organ pREservation in Muscle-invasive BLADDER Cancer)Who this might be right forMuscle Invasive Bladder Cancer (MIBC) Heinrich-Heine University, Duesseldorf 100
Testing effectiveness (Phase 2)Study completedNCT02500121What this trial is testingTesting the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder CancerWho this might be right forUrothelial CarcinomaBladder Cancer Matthew Galsky 108
Early research (Phase 1)Active Not RecruitingNCT05843448What this trial is testingIDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder CancerWho this might be right forHigh Risk Non-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8+1 more University of California, Davis 6
Testing effectiveness (Phase 2)Looking for participantsNCT06511648What this trial is testingErdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene AlterationsWho this might be right forMuscle-invasive Bladder Cancer Spanish Oncology Genito-Urinary Group 90
Not applicableUnknownNCT04588168What this trial is testingMulti-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial CarcinomaWho this might be right forBladder Cancer The First Affiliated Hospital with Nanjing Medical University 100
Testing effectiveness (Phase 2)Ended earlyNCT02887248What this trial is testingNab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial CarcinomaWho this might be right forUrothelial CarcinomaBladder CancerTransitional Cell Carcinoma SCRI Development Innovations, LLC 3
Testing effectiveness (Phase 2)Study completedNCT03159143What this trial is testingStudy of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial TractWho this might be right forMetastatic Transitional Cell Cancer of the Urothelial Tract Leonard Appleman 22
Large-scale testing (Phase 3)UnknownNCT00054626What this trial is testingCisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder CancerWho this might be right forBladder Cancer Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy 700
Testing effectiveness (Phase 2)Study completedNCT00661609What this trial is testingA Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder CancerWho this might be right forBladder CancerTransitional Cell Bladder CancerUrethra Cancer+2 more AstraZeneca 54
Testing effectiveness (Phase 2)Study completedNCT01191892What this trial is testingCarboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract CancerWho this might be right forBladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUreter Cancer+1 more Cardiff University 82
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07808216What this trial is testingToripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBTWho this might be right forNon Muscle Invasive Bladder Cancer Tianjin First Central Hospital 54
Not applicableEnded earlyNCT05568407What this trial is testingAvelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial CancerWho this might be right forBladder Cancer Pfizer 19
Early research (Phase 1)Study completedNCT02903914What this trial is testingArginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsWho this might be right forMetastatic CancerSolid TumorsColorectal Cancer (CRC)+7 more Incyte Corporation 260
Large-scale testing (Phase 3)Active Not RecruitingNCT05092958What this trial is testingTesting the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV StudyWho this might be right forAdvanced Bladder Urothelial CarcinomaAdvanced Renal Pelvis Urothelial CarcinomaAdvanced Ureter Urothelial Carcinoma+15 more National Cancer Institute (NCI) 654
Not applicableUnknownNCT05139134What this trial is testingImmunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial CarcinomaWho this might be right forUrinary Bladder Urothelial Carcinoma Sohag University 50
Testing effectiveness (Phase 2)Study completedNCT00585689What this trial is testingNeoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder CancerWho this might be right forBladder Cancer University of Michigan Rogel Cancer Center 29
Testing effectiveness (Phase 2)Study completedNCT00722553What this trial is testingStudy of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary BladderWho this might be right forCarcinoma, Transitional CellBladder CancerBladder Neoplasm Acrotech Biopharma Inc. 30
Testing effectiveness (Phase 2)Study completedNCT00343356What this trial is testingIntravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of BladderWho this might be right forBladder Neoplasms LanZhou University 138
Testing effectiveness (Phase 2)Study completedNCT02736266What this trial is testingNeoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder CarcinomaWho this might be right forUrothelial Bladder Carcinoma Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 174